Abstract
•Autologous and Allogeneic hematopoietic cell transplantation are both effective consolidative strategies in patients with Hepatosplenic T Cell Lymphoma•Median Overall Survival and Progression Free Survival for the entire cohort were 78.5 months (95% CI: 25-NR) and 54 months (95% CI: 18-75), respectively.•No significant differences in OS or PFS we seen when comparing autologous and allogeneic HCT groups.•Pts with less than CR at time of transplant had better median overall survival with allogeneic hematopoietic cell transplantation compared to autologous hematopoietic cell transplantation (65 mos. vs 7 mos., p<0.001)
: Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive type of peripheral T-cell lymphoma with median overall survival (OS) of approximately 1 year. Data on the effectiveness of hematopoietic cell transplantation (HCT) is limited, as is the choice between autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT) in the treatment of this disease.
: To evaluate the outcome of patients with HSTCL who underwent either auto-HCT or allo-HCT.
: We performed a multi-institutional retrospective cohort study to assess outcomes of HCT in HSTCL patients.
: Fifty-three patients with HSTCL were included in the study. Thirty-six patients received an allo-HCT and 17 an auto-HCT. Thirty-five (66%) were males. Median age at diagnosis was 38 (range 2–64) years. Median follow-up for survivors was 75 months (range 8-204). The median number of prior lines of therapy was 1 (range 1-4). Median OS and progression-free survival (PFS) for the entire cohort were 78.5 months (95% CI: 25-79) and 54 months (95% CI: 18-75), respectively. There were no significant differences in OS (HR: 0.63, 95% CI: 0.28-1.45, p=0.245) or PFS (HR: 0.7, 95% CI: 0.32-1.57, p=0.365) between the allo-HCT and auto-HCT groups, respectively. In the allo-HCT group, the 3-year cumulative incidence of relapse was 35% (95% CI: 21-57), while 3-year cumulative incidence of NRM was 16% (95% CI: 7-35). In the auto-HCT group, the 3-year cumulative incidence of relapse and NRM were 43% (95% CI: 23-78) and 14% (95% CI: 4-52), respectively.
: Both Auto-HCT and Allo-HCT are effective consolidative strategies in patients with HSTCL, and patients should be promptly referred for HCT evaluation.